# Fluorinated Adenosine A2A Receptor Antagonists Inspired by Preladenant as Potential Cancer Immunotherapeutics

Authors: Gengyang Yuan; Tanner C. Jankins; Christopher G. Patrick; Phaethon Philbrook; Olivia Sears; Stephen Hatfield; Michail Sitkovsky; Neil Vasdev; Steven H. Liang; Mary Jo Ondrechen; Michael P. Pollastri; Graham B. Jones
Journal: International Journal of Medicinal Chemistry
 (2017)

---

## Abstract

Antagonism of the adenosineA2A receptor on T cells blocks the hypoxia-adenosinergic pathway to promote tumor rejection. Using anin vivo immunoassay based on the Concanavalin A mouse model, a series of A2A antagonists were studied and identified preladenant as a potent lead compound for development. Molecular modeling was employed to assist drug design and subsequent synthesis of analogs and those of tozadenant, including fluorinated polyethylene glycol PEGylated derivatives. The efficacy of the analogs was evaluated using twoin vitro functional bioassays, and compound29, a fluorinated triethylene glycol derivative of preladenant, was confirmed as a potential immunotherapeutic agent.


---

## Body

## 1. Introduction

The adenosine receptors belong to the G protein-coupled receptor (GPCR) family including A1, A2A, A2B, and A3, four subtypes based on their different subcellular localization, signal transduction pathways, activation profiles, ligand binding profiles, and G protein binding preferences [1, 2]. Adenosine receptor coupling and subsequent dissociation with Gi and Gs proteins serve to regulate the level of adenylate cyclase activity, thus controlling levels of intracellular cAMP, a second messenger known to trigger a complex sequence of cellular events [1–3]. As a consequence, A2AR has become a drug discovery target of increased interest, implicated in diseases such as neurodegenerative disorders (e.g., Parkinson’s disease), cardiac ischemia, inflammation, and cancer [4–6]. After over a decade of effort applied to xanthine based A2AR antagonists, a derivative KW-6002 (istradefylline,2) was developed and approved in 2013 as an anti-Parkinson drug in Japan under the brand name Nouriast®. The molecule preladenant(4) completed Phase II clinical trials for Parkinson’s disease but failed to show efficacy in subsequent Phase III trials. However, tozadenant (SYN115,5a) entered Phase III trials in 2015 for the same indication (Figure 1) [7–9].Figure 1
Structures of selectedA2AR antagonists1–5a and A2AR agonist CGS21680 (CGS,6).Given the surge in interest inA2AR antagonists, we have focused effort on the immunomodulatory capacity of agents. We have previously demonstrated antagonism of the hypoxia-adenosinergic pathway, wherein hypoxia-driven accumulation of extracellular adenosine triggered immune suppression via A2AR activation on the surface of immune cells [10–15]. Subsequent A2AR antagonism by ZM241385(1) led to delayed growth of CL8-1 melanoma in mice and increased levels of endogenous antitumor T cells [10–15]. Derivatization of xanthine2 led to a PEG derivative (KW-PEG,3), which showed enhanced properties, including cAMP suppression and cytokine IFN-gamma restoration [16]. Spurred by these findings we were motivated to employ molecular modeling methods to design optimized derivatives (PEG) of other classes of A2AR antagonists and to explore both their immunomodulatory capacity and potential to be converted to functional imaging agents.


## 2. Materials and Methods

To select lead compounds for immunotherapy application, anin vivo Concanavalin A (ConA)-induced liver damage assay was carried out in C57BL/6 mice through the pharmacological activation and deactivation of A2ARs [17]. A variety of compounds were screened including2,3, and4 [10, 18, 19]. As shown in Figure 2, compound4 imparted the most severe immune induced liver damage and was selected as a core structure for analog design. Fluorinated analogs were envisioned to potentially serve as leads to ultimately be labeled at the distal position with fluorine-18 (t1/2=109.8 min), for diagnostic imaging with positron emission tomography (PET). A series of fluorinated PEG groups with increasing chain lengths were proposed for chemical modification to map the structure-activity relationship (SAR). Such modifications increase both hydrophilicity and molecular weight (MW), potentially to reduce blood-brain barrier (BBB) penetration as predicted by the central nervous system multiparameter optimization (MPO) score reported by Wager et al. [20].Figure 2
ConA-induced liver damage in C57BL/6 mice via CGS(6),2,3 and4. Female C57BL/6 mice (n=5) were first injected with A2AR agonist CGS (6, 2 mg kg−1), 2 mg kg−12,3, and4 separately, and then Con A (20 mg kg−1). Con A-induced liver damage evaluated at 8 h.To locate the ideal position for PEG attachment, molecular modeling was utilized based on our previously constructed homology model, which derived from the crystal structure ofA2AR in complex with1 (PDB ID 3EML) and includes a resolved EL2 cap [16, 21, 22]. This technique employed Glide (Schrödinger, version 10.4, LLC, New York, NY, 2015) extra precision (XP) docking to gain insights into the ligand-protein binding interactions [23–26]. As shown in Figure 3(a),4 almost occupies the entire binding pocket of A2AR and shares similar key binding interactions as known ligand1. Noteworthily, the methoxyethyl ether group of4 projects into the cytosolic solution and forms an additional H-bond with Pro266 at the solvent-exposed surface of the A2AR, connecting with the cytosolic solution. Similarly, the current clinical candidate5a also occupies a position near the edge of the A2AR binding pocket, where the piperidine quaternary alkyl group forms hydrophobic interactions with Leu267 and His264 and the tertiary alcohol group forms a hydrogen bond with Glu169 (Figure 3(b)) [27, 28]. It was thus suggested that introduction of hydrophilic and fluorinated PEG groups at the phenolic position of4 and the piperidine component of5a would not impact key binding events of their core structures as the pendant groups would be capable of engaging in hydrogen bonds at the termini or in the case of their chains via hydrated networks. Accordingly, the octaethylene glycol monomethyl ether moiety, a tolerable substituent in prior studies on compound2 [16] in conjunction with the phenyl-piperazine linker inherent in4, was introduced to5a and syntheses designed. In addition, synthesis of a demethylated version of the compound(5b) was planned, as such could be a useful intermediate for radiotracer synthesis (as either [11C]5a via a one-step [11C]CH3I methylation or a base-promoted coupling with an 18F-labeled short alkyl chain) at this locus.Figure 3
Glide XP docking results of4 and5a. The interacting residues of A2AR are colored grey and the H-bond is represented as a dotted line. (a)4 and (b)5a renderings from YASARA [39].
(a)
(b)Synthesis of reference compounds2 and3 was performed using refinements of reported methods which produced superior yields independent of scale [16]. For example, use of a mild (AIBN/NBS promoted) route to the 8-substituted xanthine scaffold resulted in an improvement in yield from 22% to 56% for this key step (see experimental section) [29]. Compounds4 and5a were synthesized based on modified literature methods (Scheme 1) [30–33], key intermediate13 obtained from compound7 via Vilsmeier-promoted halogenation and formylation, one-pot cascade condensation with 2-furoic acid hydrazine(9) and 2-hydroxyethyl hydrazine(11), Dimroth rearrangement to effect triazole formation, and finally bromination with POCl3/ZnBr2. The piperazine components were prepared starting from either commercially available fragment14 or fluorination/activation of the known mono- or ditosylated PEG chains(15–19) and subsequent coupling reaction with 1-(4-(4-hydroxyphenyl) piperazin-1-yl)ethan-1-one(20) and then deacetylation prior to the final coupling reaction with intermediate13 to furnish4 and the desired analogs27–31 [30, 34].Scheme 1
Synthesis of4 and its PEGylated analogs. Conditions: (a) POCl3, DMF, 78%; (b) 2-furoic acid hydrazide(9), Na2CO3, MeCN; (c) 2-hydroxyethyl hydrazine(11), 78% over 2 steps; (d) POCl3, ZnBr2, 45%; (e) (i) NaH, DMF; (ii) 6 N HCl. 67% (n=0, 21), 62% (n=1, 22), 56% (n=2, 23), 35% (n=5, 24), 70% (n=1, 25), 70% (n=7, 26); (f)N,N-diisopropylethylamine (DIPEA), DMF, 52% (n=0,27), 47% (n=1,28), 33% (n=2,29), 25% (n=5,30), 55% (n=1,4), and 25% (n=7,31).Synthesis of5a is illustrated in Scheme 2. The bromide32 was subjected to palladium-catalyzed coupling with morpholine(33), stannous nitro reduction, condensation with benzoyl isothiocyanate, bromine promoted formation of the benzothiazole ring, and installation of the piperidine ring through intermediate38. Preparation of analog40 was achieved via coupling of26 and38 [31]. Direct demethylation of5a with BBr3 did not lead to the desired product5b but instead led to decomposition and bromination of the tertiary alcohol [34]. Likewise,l-selectride promoted demethylation of5a led to very poor yield of product5b (5%) [35]. The sequence was finally realized when the phenyl carbamate protecting group of38 was employed. With demethylation achieved, the phenyl carbamate protecting group (of41) was replaced by 4-methylpiperidin-4-ol39 to afford desmethyl tozadenant,5b. Full details of all experimental procedures, bioassays, and molecular modeling are described in the Supplementary Material available online at https://doi.org/10.1155/2017/4852537.Scheme 2
Synthesis of5a,5b, and PEGylated analog40. Conditions: (a) morpholine(33), K3PO4, 2-biphenyl-dicyclohexylphosphine, Pd(OAc)2, dimethoxyethane, 37%; (b) Sn powder, EtOH/con.HCl, 66%; (c) benzoyl isothiocyanate, acetone, 99%; (d) (i) NaOMe, MeOH; (ii) Br2, CHCl3, 73%; (e) phenyl carbonochloridate, pyridine, dichloromethane, 94%; (f) 4-methylpiperidin-4-ol hydrochloride(39), DIPEA, THF, CHCl3, 53%; (g)26, DIPEA, THF, CHCl3, 28%; (h) BBr3, dichloromethane, 52%; (i)(39), DIPEA, THF, CHCl3, 62%.


## 3. Results and Discussion

Bioassay of compounds27–31 and40 and their parent compounds (4 and5a) was conducted using two functional assays that evaluate A2AR binding-dependent signaling through A2AR on the surface of T cells [16]. The first assay screens compounds on the basis of their extent of inhibition of A2AR-induced intracellular cAMP accumulation in A2AR expressing lymphocytes [36, 37]. The A2AR agonist, CGS21680 (CGS,6), was used to activate A2AR. As shown in Figure 4, all of the above compounds, except40, were able to prevent CGS-mediated signaling. Stronger antagonism was observed for the preladenant-based analogs27–29 versus the previously evaluated compounds2 and3. Further increments of the PEG chain length resulted in decreased antagonism (compounds30 and31). Surprisingly,5a showed inferior antagonism to that of compounds2 and3, and its derivative40 exhibited no suppression of intracellular cAMP accumulation.Figure 4
Intracellular cAMP levels in lymphocytes after incubation with vehicle, 1µM CGS, and 1 µM CGS plus 1 μM of compounds4 (preladenant),27–31,5a (tozadenant),40,2 (KW-6002), and3 (KW-PEG) are shown. The intracellular cAMP levels were determined 15 min following stimulation using quantitative cAMP ELISA and are expressed as fmol/106 cells. Data shown represent mean ± SEM of triplicate samples.An evaluation of the positive hits in the cAMP assay(27–29) was carried out in silico by Glide docking to study their binding orientation in A2AR. The docking results confirmed the initial assumption for such analog design (Figure 5), the core structures of27–29 anchoring in similar positions as4, forming identical key binding interactions with Asn253, Glu169, and Phe168. The installed PEG chains interact with the residues at the edge of A2AR via hydrophobic and H-bonding interactions.Figure 5
Docking results of27–29 via Glide XP method. The interacting residues of A2AR are colored grey and the H-bond is represented as cyan dotted line. (a) Compound27. (b) Compound28. (c) Compound29. Rendered from YASARA [39].
(a)
(b)
(c)The second immunoassay assesses secretion of the cytokine IFN-gamma, since it is considered to be sensitive to theA2AR signaling pathway [16]. In these assays, during T cell receptor (TCR) activation by the CD3 ligand, C57BL/6 mice splenocytes T cells are incubated with A2AR agonist CGS to inhibit IFN-gamma secretion resulting from A2AR-induced immunosuppression via intracellular cAMP. Effective A2AR antagonists block the A2AR-activated signal, thus restoring secretion of the cytokine to potentiate and prolong the immune response. Compounds29,2,3, and4 were evaluated (Figure 6), and compound29 showed similar capacity to that of4, both of which resulted in superior restoration of IFN-gamma secretion compared to either2 or3.Figure 6
The IFN-gamma production by splenocytes after activation with 0.1µg/mL anti-CD3 and when treated with vehicle, 1 µM CGS, and 1 µM CGS plus 1 µM compounds29,2 (KW-6002),3 (KW-PEG), and4 (preladenant) separately is shown. The IFN-gamma levels were determined in the supernatant one day following stimulation using quantitative ELISA and are expressed as pg/mL. Data shown represent mean ± SEM of triplicate samples.Given the promising results in functional assays, the physicochemical properties of compound29 and its homologs were determined, including its log⁡D7.4, aqueous solubility, human plasma protein binding (PPB), and metabolic stability [human liver microsome and rat hepatocyte clearance] as shown in Table 1. Broadly similar results were obtained, principle differences being enhanced aqueous solubility for27, whereas intrinsic clearance was superior for29 in the rodent derived line and for28 in the human cell line. Reduced clearance for27 in turn may bode well for use in biodistribution studies [38].Table 1
Physicochemical properties and docking results of compounds27–29.
Compound
Glide score
log
⁡
D
7.4
Aqueous solubility (μM)
Human PPB (%)
HLM CLint (μL/min/mg)
Rat hepatocyte CLint (μL/min/106)
27
−12.2
2.8
74
99
16.5
29.9
28
−11.8
2.5
2
98.7
71.9
12.8
29
−12.3
2.3
10
98.3
66.1
72.9


## 4. Conclusions

In summary, we have designed and synthesized a family of PEGylated analogs of4 and5a using molecular modeling techniques. Lead compound29, a fluorinated triethylene glycol derivative of preladenant, was identified, which shows promising results in two functional immunoassays and physicochemical assays. Future work will focus on detailed mechanistic studies on the mode of action of29 and investigation of its use as a potential cancer immunotherapeutic agent.



---

*Source: 4852537-2017-10-19.xml*